Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device-controlled, double-blind study
- PMID: 24474647
- PMCID: PMC3986893
- DOI: 10.1007/s40257-013-0060-6
Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham device-controlled, double-blind study
Abstract
Significance: Male and female pattern hair loss are common, chronic dermatologic disorders with limited therapeutic options. In recent years, a number of commercial devices using low-level laser therapy have been promoted, but there have been little peer-reviewed data on their efficacy.
Objective: To determine whether treatment with a low-level laser device, the US FDA-cleared HairMax Lasercomb®, increases terminal hair density in both men and women with pattern hair loss.
Methods: Randomized, sham device-controlled, double-blind clinical trials were conducted at multiple institutional and private practices. A total of 146 male and 188 female subjects with pattern hair loss were screened. A total of 128 male and 141 female subjects were randomized to receive either a lasercomb (one of three models) or a sham device in concealed sealed packets, and were treated on the whole scalp three times a week for 26 weeks. Terminal hair density of the target area was evaluated at baseline and at 16- and 26-week follow-ups, and analyzed to determine whether the hypothesis formulated prior to data collection, that lasercomb treatment would increase terminal hair density, was correct. The site investigators and the subjects remained blinded to the type of device they dispensed/received throughout the study. The evaluator of masked digital photographs was blinded to which trial arm the subject belonged.
Results: Seventy-eight, 63, 49, and 79 subjects were randomized in four trials of 9-beam lasercomb treatment in female subjects, 12-beam lasercomb treatment in female subjects, 7-beam lasercomb treatment in male subjects, and 9- and 12-beam lasercomb treatment in male subjects, compared with the sham device, respectively. Nineteen female and 25 male subjects were lost to follow-up. Among the remaining 122 female and 103 male subjects in the efficacy analysis, the mean terminal hair count at 26 weeks increased from baseline by 20.2, 20.6, 18.4, 20.9, and 25.7 per cm2 in 9-beam lasercomb-treated female subjects, 12-beam lasercomb-treated female subjects, 7-beam lasercomb-treated male subjects, and 9- and 12-beam lasercomb-treated male subjects, respectively, compared with 2.8 (p<0.0001), 3.0 (p<0.0001), 1.6 (p=0.0017), 9.4 (p=0.0249), and 9.4 (p=0.0028) in sham-treated subjects (95% confidence interval). The increase in terminal hair density was independent of the age and sex of the subject and the lasercomb model. Additionally, a higher percentage of lasercomb-treated subjects reported overall improvement of hair loss condition and thickness and fullness of hair in self-assessment, compared with sham-treated subjects. No serious adverse events were reported in any subject receiving the lasercomb in any of the four trials.
Conclusions and relevance: We observed a statistically significant difference in the increase in terminal hair density between lasercomb- and sham-treated subjects. No serious adverse events were reported. Our results suggest that low-level laser treatment may be an effective option to treat pattern hair loss in both men and women. Additional studies should be considered to determine the long-term effects of low-level laser treatment on hair growth and maintenance, and to optimize laser modality.
Figures
Similar articles
-
HairMax LaserComb laser phototherapy device in the treatment of male androgenetic alopecia: A randomized, double-blind, sham device-controlled, multicentre trial.Clin Drug Investig. 2009;29(5):283-92. doi: 10.2165/00044011-200929050-00001. Clin Drug Investig. 2009. PMID: 19366270 Clinical Trial.
-
Low-level laser therapy for the treatment of androgenetic alopecia in Thai men and women: a 24-week, randomized, double-blind, sham device-controlled trial.Lasers Med Sci. 2019 Aug;34(6):1107-1114. doi: 10.1007/s10103-018-02699-9. Epub 2018 Dec 19. Lasers Med Sci. 2019. PMID: 30569416 Clinical Trial.
-
The growth of human scalp hair in females using visible red light laser and LED sources.Lasers Surg Med. 2014 Oct;46(8):601-7. doi: 10.1002/lsm.22277. Epub 2014 Aug 13. Lasers Surg Med. 2014. PMID: 25124964 Free PMC article. Clinical Trial.
-
Interventions for female pattern hair loss.Cochrane Database Syst Rev. 2016 May 26;2016(5):CD007628. doi: 10.1002/14651858.CD007628.pub4. Cochrane Database Syst Rev. 2016. PMID: 27225981 Free PMC article. Review.
-
Low-level laser treatment accelerated hair regrowth in a rat model of chemotherapy-induced alopecia (CIA).Lasers Med Sci. 2013 May;28(3):701-6. doi: 10.1007/s10103-012-1139-7. Epub 2012 Jun 14. Lasers Med Sci. 2013. PMID: 22696077
Cited by
-
Role of Low-Level Light Therapy (LLLT) in Androgenetic Alopecia.J Cutan Aesthet Surg. 2021 Oct-Dec;14(4):385-391. doi: 10.4103/JCAS.JCAS_218_20. J Cutan Aesthet Surg. 2021. PMID: 35283601 Free PMC article. Review.
-
Induction of hair growth in hair follicle cells and organ cultures upon treatment with 30 kHz frequency inaudible sound via cell proliferation and antiapoptotic effects.Biomed Rep. 2022 Mar;16(3):16. doi: 10.3892/br.2022.1499. Epub 2022 Jan 18. Biomed Rep. 2022. PMID: 35223000 Free PMC article.
-
Advances in hair growth.Fac Rev. 2022 Jan 12;11:1. doi: 10.12703/r/11-1. eCollection 2022. Fac Rev. 2022. PMID: 35156098 Free PMC article. Review.
-
Efficacy assessment for low-level laser therapy in the treatment of androgenetic alopecia: a real-world study on 1383 patients.Lasers Med Sci. 2022 Aug;37(6):2589-2594. doi: 10.1007/s10103-022-03520-4. Epub 2022 Feb 8. Lasers Med Sci. 2022. PMID: 35133519 Free PMC article.
-
A Systematic Review and Meta-analysis of Randomized Controlled Trials of United States Food and Drug Administration-Approved, Home-use, Low-Level Light/Laser Therapy Devices for Pattern Hair Loss: Device Design and Technology.J Clin Aesthet Dermatol. 2021 Nov;14(11):E64-E75. J Clin Aesthet Dermatol. 2021. PMID: 34980962 Free PMC article.
References
-
- Hoffmann R, Happle R. Current understanding of androgenetic alopecia: Part I. Etiopathogenesis. Eur J Dermatol. 2000;10(4):319–327. - PubMed
-
- McElwee KJ, Shapiro JS. Promising therapies for treating and/or preventing androgenic alopecia. Skin Therapy Lett. 2012;17(6):1–4. - PubMed
-
- Rangwala S, Rashid RM. Alopecia: a review of laser and light therapies. Dermatol Online J. 2012;18(2):3. - PubMed
Publication types
MeSH terms
Grant support
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
